After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...

Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...